MagVenture A/S

MagVenture is a privately owned Danish manufacturer of Transcranial Magnetic Stimulation (TMS) and Magnetic Peripheral Nerve Stimulation (mPNS) systems. The company has pioneered non-invasive TMS technology for over 30 years, serving clinicians, researchers, and diagnosticians globally. Products are designed, developed, produced, and quality-tested in Denmark and distributed through subsidiaries in the USA, Brazil, UK, China, and Germany, with presence in more than 70 countries. MagVenture TMS systems are FDA-cleared for treatment of Major Depressive Disorder (MDD) in adults and adolescents (15–21 years), Obsessive-Compulsive Disorder (OCD), anxiety-comorbid depression, and pain therapy. Systems also support diagnostic applications for stimulation of central and peripheral nervous systems, electrophysiological assessment via motor evoked potentials (MEP), and research in neuroscience, neurophysiology, neuroplasticity, and cognitive neuroscience. The company offers multiple therapy packages (R20, R30 standard and accelerated variants) with optional neuronavigation systems (Localite-Value and Localite-Premium), cooling systems, and specialized coils including the new T65 generation. Clinical support includes training, clinical protocols for standard and accelerated rTMS, and ongoing technical service.